Data from multiple sources - Curated by Marshall Pearce - Last updated 06 June 2017

Latest news articles

Added 17 days ago Drug news

NICE now supports Tecentriq to treat Bladder Cancer. Roche.

The National Institute for Health and Care Excellence (NICE) has now recommended that Tecentriq (atezolizumab) from Roche may be used within...

Search all news articles for Cancer of bladder
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breakthrough Cancer Pain Learning Zone

Breakthrough Cancer Pain Learning Zone

Watch video hightlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.

Prostate Cancer

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

+ 5 more

Load more

Guidelines

Guidelines on Upper Urinary Tract Urothelial Cell Carcinomas

The European Association of Urology (EAU) Non-muscle-invasive Bladder Cancer (NMIBC) Guidelines Panel has compiled these clinical guidelines to provide urologists...

Added 1 year ago

Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS)

This overview represents the updated European Association of Urology (EAU) guidelines for Non-muscle-invasive Bladder Cancer (CIS, Ta, T1). The information...

Added 1 year ago

Guidelines on Muscle-invasive and Metastatic Bladder Cancer

The European Association of Urology (EAU) Guidelines Panel for Muscle-invasive and Metastatic Bladder Cancer (MIBC) has prepared these guidelines to...

Added 1 year ago

Search all guidelines for Cancer of bladder
 

Journal articles

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.

Until recently in the United States, no products were approved for second-line treatment of advanced urothelial carcinoma. On May 18, 2016, the U.S. Food and Drug Administration approved atezolizumab for the treatment...

Added 1 month ago

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.

In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials.

Added 1 month ago

Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.

Metastatic urothelial carcinoma of the bladder is an aggressive malignancy with poor prognosis, reflecting a lack of effective systemic therapies. The current standard of care includes multiagent platinum-based chemotherapy...

Added 1 month ago

Search all journal articles for Cancer of bladder
 

Clinical trials

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE)

The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.

Added 1 month ago

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic...

Added 1 month ago

Search all clinical trials for Cancer of bladder
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

CME

Carcinoma of unknown primary origin: diagnosis and management: putting NICE guidelines into practice

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Cancer of bladder